These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38117666)

  • 21. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
    He Y; Ren XJ; Hu BJ; Lam WC; Li XR
    BMC Ophthalmol; 2018 May; 18(1):121. PubMed ID: 29784048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.
    Elwes F; Borooah S; Aspinall P; Sim PY; Loo CY; Armbrecht AM; Dhillon B; Cackett P
    BMC Ophthalmol; 2018 Jan; 18(1):20. PubMed ID: 29378528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration.
    Abdolrahimzadeh S; Gharbiya M; Formisano M; Bertini F; Cerini A; Pacella E
    Curr Eye Res; 2019 Sep; 44(9):1000-1005. PubMed ID: 30999772
    [No Abstract]   [Full Text] [Related]  

  • 29. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
    Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study.
    Chiquet C; Dupuy C; Bron AM; Aptel F; Straub M; Isaico R; Romanet JP; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2095-102. PubMed ID: 25673251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.
    Verbraak FD; Ponsioen DL; Tigchelaar-Besling OAM; Nguyen V; Gillies MC; Barthelmes D; Klaver CCW
    Acta Ophthalmol; 2021 Sep; 99(6):e884-e892. PubMed ID: 33354933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment.
    Zola M; D'Alessandro E; Sherif M; Nguyen A; De Azevedo D; Haeller C; Forestier E; Mantel I
    Graefes Arch Clin Exp Ophthalmol; 2021 Jun; 259(6):1477-1486. PubMed ID: 33245426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
    Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
    Front Immunol; 2021; 12():738521. PubMed ID: 34721402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD.
    Fassnacht-Riederle H; Becker M; Graf N; Michels S
    Graefes Arch Clin Exp Ophthalmol; 2014 Nov; 252(11):1705-9. PubMed ID: 24614949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.